Abstract
Malaria, caused by protozoa of the genus Plasmodium, remains one of the most dreadful infectious diseases worldwide killing more than 1 million people per year. The emergence of multidrug-resistant parasites highly demands a steadfast and continuous search not only for new targets but also for new anti-infectives addressing the known ones. As proteases in general have been proven to be excellent drug targets and the development of inhibitors has frequently resulted in approved drugs, this review will only focus on the proteases of Plasmodium falciparum as drug targets. The completion of the sequencing of the Plasmodium falciparum genome in 2002 lead to the discovery of nearly 100 putative proteases encoded therein. Within this review, only those proteases and inhibitors thereof will be discussed in more detail, in which their biological function has been determined undoubtedly or in those cases, in which the development of specific inhibitors has significantly contributed to the understanding of the underlying biological role of the respective protease thus validating the role as promising drug target.
Keywords: Malaria, Plasmepsin, Falcipain, protease inhibitors
Current Topics in Medicinal Chemistry
Title: Proteases of Plasmodium falciparum as Potential Drug Targets and Inhibitors Thereof
Volume: 10 Issue: 3
Author(s): Christof Wegscheid-Gerlach, Hans-Dieter Gerber and Wibke E. Diederich
Affiliation:
Keywords: Malaria, Plasmepsin, Falcipain, protease inhibitors
Abstract: Malaria, caused by protozoa of the genus Plasmodium, remains one of the most dreadful infectious diseases worldwide killing more than 1 million people per year. The emergence of multidrug-resistant parasites highly demands a steadfast and continuous search not only for new targets but also for new anti-infectives addressing the known ones. As proteases in general have been proven to be excellent drug targets and the development of inhibitors has frequently resulted in approved drugs, this review will only focus on the proteases of Plasmodium falciparum as drug targets. The completion of the sequencing of the Plasmodium falciparum genome in 2002 lead to the discovery of nearly 100 putative proteases encoded therein. Within this review, only those proteases and inhibitors thereof will be discussed in more detail, in which their biological function has been determined undoubtedly or in those cases, in which the development of specific inhibitors has significantly contributed to the understanding of the underlying biological role of the respective protease thus validating the role as promising drug target.
Export Options
About this article
Cite this article as:
Wegscheid-Gerlach Christof, Gerber Hans-Dieter and Diederich E. Wibke, Proteases of Plasmodium falciparum as Potential Drug Targets and Inhibitors Thereof, Current Topics in Medicinal Chemistry 2010; 10(3) . https://dx.doi.org/10.2174/156802610790725461
DOI https://dx.doi.org/10.2174/156802610790725461 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Cellomics as Integrative Omics for Cancer
Current Proteomics Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Anticancer Agents: Towards the Future
Current Medicinal Chemistry - Anti-Cancer Agents CIITA and the MHCII Enhanceosome in the Regulation of MHCII Expression
Current Genomics Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design Hematopoietic Stem Cells: Source Matters
Current Stem Cell Research & Therapy Potent Phosphatidylinositol 3-Kinase Inhibitors and Their Biology
Current Drug Discovery Technologies DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now
Current Drug Delivery Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Hsp90 Inhibitors: From Discovery to Clinic
Anti-Cancer Agents in Medicinal Chemistry Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors
Current Medicinal Chemistry Advances in Clinical Study of Curcumin
Current Pharmaceutical Design